US5662896A
(en)
|
1988-03-21 |
1997-09-02 |
Chiron Viagene, Inc. |
Compositions and methods for cancer immunotherapy
|
US5997859A
(en)
*
|
1988-03-21 |
1999-12-07 |
Chiron Corporation |
Method for treating a metastatic carcinoma using a conditionally lethal gene
|
US6133029A
(en)
*
|
1988-03-21 |
2000-10-17 |
Chiron Corporation |
Replication defective viral vectors for infecting human cells
|
US6569679B1
(en)
|
1988-03-21 |
2003-05-27 |
Chiron Corporation |
Producer cell that generates adenoviral vectors encoding a cytokine and a conditionally lethal gene
|
US5716826A
(en)
*
|
1988-03-21 |
1998-02-10 |
Chiron Viagene, Inc. |
Recombinant retroviruses
|
JP2752788B2
(ja)
*
|
1989-01-23 |
1998-05-18 |
カイロン コーポレイション |
感染および過剰増殖障害の為の組換え療法
|
JPH04504361A
(ja)
*
|
1989-04-05 |
1992-08-06 |
ノバセル コーポレイション |
感染性標的化複製―欠陥ビリオン
|
US6337209B1
(en)
|
1992-02-26 |
2002-01-08 |
Glaxo Wellcome Inc. |
Molecular constructs containing a carcinoembryonic antigen regulatory sequence
|
US6555370B1
(en)
|
1990-11-13 |
2003-04-29 |
Immunex Corporation |
Bifunctional selectable fusion genes
|
JP3150340B2
(ja)
*
|
1990-11-13 |
2001-03-26 |
イムネクス コーポレイション |
二機能選択可能融合遺伝子
|
GB9100612D0
(en)
*
|
1991-01-11 |
1991-02-27 |
Univ Edinburgh |
Method of altering the metabolic state of non-dividing cells,transgenic animals and therapeutic agents
|
GB9104165D0
(en)
*
|
1991-02-27 |
1991-04-17 |
Wellcome Found |
Novel entities for hiv therapy
|
GB9107631D0
(en)
*
|
1991-04-10 |
1991-05-29 |
British Bio Technology |
Proteinaceous particles
|
US5358866A
(en)
*
|
1991-07-03 |
1994-10-25 |
The United States Of America As Represented By The Department Of Health And Human Services |
Cytosine deaminase negative selection system for gene transfer techniques and therapies
|
US5529774A
(en)
*
|
1991-08-13 |
1996-06-25 |
The Regents Of The University Of California |
In vivo transfer of the HSV-TK gene implanted retroviral producer cells
|
ES2142834T3
(es)
*
|
1991-10-30 |
2000-05-01 |
Univ Paris Curie |
Celulas transformadas para la prevencion o el tratamiento de enfermedades inducidas por virus, en particular retrovirus patogenos.
|
WO1993010218A1
(en)
*
|
1991-11-14 |
1993-05-27 |
The United States Government As Represented By The Secretary Of The Department Of Health And Human Services |
Vectors including foreign genes and negative selective markers
|
WO1994004196A1
(en)
*
|
1992-08-14 |
1994-03-03 |
Imperial Cancer Research Technology Limited |
Tumour therapy
|
GB9305759D0
(en)
*
|
1993-03-19 |
1993-05-05 |
Medical Research Council And T |
Hiv therapy method and agents
|
US6017896A
(en)
*
|
1993-09-14 |
2000-01-25 |
University Of Alabama Research Foundation And Southern Research Institute |
Purine nucleoside phosphorylase gene therapy for human malignancy
|
US5552311A
(en)
*
|
1993-09-14 |
1996-09-03 |
University Of Alabama At Birmingham Research Foundation |
Purine nucleoside phosphorylase gene therapy for human malignancy
|
US6491905B1
(en)
|
1993-09-14 |
2002-12-10 |
The Uab Research Foundation |
Recombinant bacterial cells for delivery of PNP to tumor cells
|
US5804407A
(en)
*
|
1993-11-04 |
1998-09-08 |
University Technologies International, Inc. |
Method of expressing genes in mammalian cells
|
JPH09503920A
(ja)
*
|
1993-11-18 |
1997-04-22 |
チロン ビアジーン,インコーポレイティド |
条件致死遺伝子を利用する組成物及び方法
|
FR2712602B1
(fr)
*
|
1993-11-18 |
1996-02-09 |
Centre Nat Rech Scient |
Virus recombinants, préparation et utilisation en thérapie génique.
|
FR2712603B1
(fr)
*
|
1993-11-18 |
1996-02-09 |
Centre Nat Rech Scient |
Virus recombinants, préparation et utilisation en thérapie génique.
|
ATE211174T1
(de)
*
|
1994-05-02 |
2002-01-15 |
Univ Washington |
Thymidin-kinase-mutanten
|
US6451571B1
(en)
|
1994-05-02 |
2002-09-17 |
University Of Washington |
Thymidine kinase mutants
|
GB9415167D0
(en)
*
|
1994-07-27 |
1994-09-14 |
Springer Caroline J |
Improvements relating to cancer therapy
|
PL184375B1
(pl)
*
|
1994-09-02 |
2002-10-31 |
Gsfforschungszentrum Für Umwelt Und Gesundheit Gmbh |
Wektor retrowirusowy podlegający konwersji promotora, układ wektora retrowirusowego, sposób wytwarzania prowirusa retrowirusowego, sposób wytwarzania cząstki retrowirusa rekombinowanego, kompozycja farmaceutyczna, mRNA retrowirusowego prowirusa wytworzonego na drodze transkrypcji wektora retrowirusowego podlegającego konwersji promatora, RNA wektora retrowirusowego podlegającego konwersji promotora oraz sposóby wytwarzania kompozycji farmaceutycznej
|
GB9422383D0
(en)
*
|
1994-11-05 |
1995-01-04 |
Wellcome Found |
Antibodies
|
GB9423367D0
(en)
*
|
1994-11-18 |
1995-01-11 |
Wellcome Found |
Enzyme prodrug therapy
|
US5998205A
(en)
|
1994-11-28 |
1999-12-07 |
Genetic Therapy, Inc. |
Vectors for tissue-specific replication
|
US6638762B1
(en)
|
1994-11-28 |
2003-10-28 |
Genetic Therapy, Inc. |
Tissue-vectors specific replication and gene expression
|
DE69627644T2
(de)
|
1995-03-09 |
2004-02-19 |
GSF-Forschungszentrum für Umwelt und Gesundheit GmbH |
Vektoren, die therapeutische gene fuer antimikrobielle peptide enthalten, zur verwendung in der gentherapie
|
US6254862B1
(en)
|
1997-03-03 |
2001-07-03 |
Calydon, Inc. |
Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof
|
US7011976B1
(en)
|
1997-03-03 |
2006-03-14 |
Calydon, Inc. |
Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof
|
US6676935B2
(en)
|
1995-06-27 |
2004-01-13 |
Cell Genesys, Inc. |
Tissue specific adenoviral vectors
|
GB9516943D0
(en)
*
|
1995-08-18 |
1995-10-18 |
Cancer Soc Auckland Div Nz Inc |
Novel cyclopropylindoles and their secoprecursors,and their use as prodrugs
|
GB9517001D0
(en)
*
|
1995-08-18 |
1995-10-18 |
Denny William |
Enediyne compounds
|
US6248555B1
(en)
|
1995-08-31 |
2001-06-19 |
The General Hospital Corporation |
Genetic alterations related to familial alzheimer's disease
|
GB9523703D0
(en)
*
|
1995-11-20 |
1996-01-24 |
Wellcome Found |
Enzyme prodrug thearapy
|
CN1062602C
(zh)
*
|
1996-01-25 |
2001-02-28 |
上海市肿瘤研究所 |
中国株单纯疱疹病毒胸苷激酶基因及其应用
|
US5952221A
(en)
|
1996-03-06 |
1999-09-14 |
Avigen, Inc. |
Adeno-associated virus vectors comprising a first and second nucleic acid sequence
|
US6130237A
(en)
*
|
1996-09-12 |
2000-10-10 |
Cancer Research Campaign Technology Limited |
Condensed N-aclyindoles as antitumor agents
|
CA2266656A1
(en)
|
1996-09-17 |
1998-03-26 |
Chiron Corporation |
Compositions and methods for treating intracellular diseases
|
US6544523B1
(en)
|
1996-11-13 |
2003-04-08 |
Chiron Corporation |
Mutant forms of Fas ligand and uses thereof
|
GB9701425D0
(en)
|
1997-01-24 |
1997-03-12 |
Bioinvent Int Ab |
A method for in vitro molecular evolution of protein function
|
GB9709421D0
(en)
|
1997-05-10 |
1997-07-02 |
Zeneca Ltd |
Chemical compounds
|
GB9712370D0
(en)
|
1997-06-14 |
1997-08-13 |
Aepact Ltd |
Therapeutic systems
|
GB9712512D0
(en)
|
1997-06-16 |
1997-08-20 |
Bioinvent Int Ab |
A method for in vitro molecular evolution of protein function
|
DE69838584T2
(de)
|
1997-08-04 |
2008-06-26 |
Cell Genesys, Inc., Foster City |
Enhancer des menschlichen glandulären kallikreingens, vektoren die ihn enthalten und methoden für seine verwendung
|
DE69838483T2
(de)
|
1997-10-14 |
2008-07-03 |
Darwin Molecular Corp. |
Thymidinkinase mutanten und fusionproteine mit thymidinkinase und guanylatekinase aktivitäten
|
US6914131B1
(en)
|
1998-10-09 |
2005-07-05 |
Chiron S.R.L. |
Neisserial antigens
|
CA2308606A1
(en)
|
1997-11-06 |
1999-05-20 |
Chiron S.P.A. |
Neisserial antigens
|
EP2278011A3
(en)
|
1998-01-14 |
2012-03-07 |
Novartis Vaccines and Diagnostics S.r.l. |
Neisseria meningitidis antigens
|
US6410328B1
(en)
|
1998-02-03 |
2002-06-25 |
Protiva Biotherapeutics Inc. |
Sensitizing cells to compounds using lipid-mediated gene and compound delivery
|
AU761780B2
(en)
|
1998-05-01 |
2003-06-12 |
Glaxosmithkline Biologicals Sa |
Neisseria meningitidis antigens and compositions
|
JP2002527066A
(ja)
|
1998-10-15 |
2002-08-27 |
カイロン コーポレイション |
転移性乳癌および結腸癌調節遺伝子
|
CA2352532C
(en)
|
1998-11-27 |
2014-10-14 |
Darwin Discovery Ltd. |
Compositions and methods for increasing bone mineralization
|
US20040009535A1
(en)
|
1998-11-27 |
2004-01-15 |
Celltech R&D, Inc. |
Compositions and methods for increasing bone mineralization
|
PT1141331E
(pt)
|
1998-12-16 |
2008-12-22 |
Novartis Vaccines & Diagnostic |
Quinase dependente de ciclina humana (hpnqalre)
|
US7063850B1
(en)
|
1998-12-22 |
2006-06-20 |
University Of Tennessee Research Foundation |
Protective antigen of group A Streptococci
|
JP2002533124A
(ja)
|
1998-12-31 |
2002-10-08 |
カイロン コーポレイション |
Hivポリペプチドの改善された発現およびウイルス様粒子の生成
|
US7935805B1
(en)
|
1998-12-31 |
2011-05-03 |
Novartis Vaccines & Diagnostics, Inc |
Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
|
GB9907414D0
(en)
|
1999-03-31 |
1999-05-26 |
Cancer Res Campaign Tech |
Improvements relating to prodrugs
|
US6864235B1
(en)
|
1999-04-01 |
2005-03-08 |
Eva A. Turley |
Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
|
US6911429B2
(en)
|
1999-04-01 |
2005-06-28 |
Transition Therapeutics Inc. |
Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
|
EP1228217B1
(en)
|
1999-04-30 |
2012-11-21 |
Novartis Vaccines and Diagnostics S.r.l. |
Conserved neisserial antigens
|
GB9911683D0
(en)
|
1999-05-19 |
1999-07-21 |
Chiron Spa |
Antigenic peptides
|
GB9916529D0
(en)
|
1999-07-14 |
1999-09-15 |
Chiron Spa |
Antigenic peptides
|
US20030108539A1
(en)
|
2000-02-14 |
2003-06-12 |
Christophe Bonny |
Cell-permeable peptide inhibitors of the JNK signal transduction pathway
|
AU784203B2
(en)
|
1999-10-29 |
2006-02-23 |
Glaxosmithkline Biologicals S.A. |
Neisserial antigenic peptides
|
PT1232264E
(pt)
|
1999-11-18 |
2009-11-26 |
Novartis Vaccines & Diagnostic |
Gene fgf-21 humano e produtos da expressão do gene
|
EP2275129A3
(en)
|
2000-01-17 |
2013-11-06 |
Novartis Vaccines and Diagnostics S.r.l. |
Outer membrane vesicle (OMV) vaccine comprising N. meningitidis serogroup B outer membrane proteins
|
EP1854476A3
(en)
|
2000-02-09 |
2008-05-07 |
Bas Medical, Inc. |
Use of relaxin to treat diseases related to vasoconstriction
|
JP4763210B2
(ja)
|
2000-02-28 |
2011-08-31 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル |
ナイセリアのタンパク質の異種発現
|
US20030036524A1
(en)
*
|
2000-03-08 |
2003-02-20 |
Jens Licthenberg |
Method of sensitising endothelial cells to prodrugs
|
JP2003531583A
(ja)
|
2000-03-08 |
2003-10-28 |
カイロン コーポレイション |
ヒトfgf−23遺伝子および遺伝子発現産物
|
EP1950297A2
(en)
|
2000-05-31 |
2008-07-30 |
Novartis Vaccines and Diagnostics, Inc. |
Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers
|
US6656718B2
(en)
|
2000-07-07 |
2003-12-02 |
Cancer Research Technology Limited |
Modified carboxypeptidase enzymes and their use
|
MX357775B
(es)
|
2000-10-27 |
2018-07-20 |
J Craig Venter Inst Inc |
Acidos nucleicos y proteinas de los grupos a y b de estreptococos.
|
DE10055383A1
(de)
*
|
2000-11-08 |
2002-05-29 |
Max Delbrueck Centrum |
Verwendung des humanen LRP/MVP Promotors für einen Therapie-induzierbaren Vektor
|
US6958213B2
(en)
|
2000-12-12 |
2005-10-25 |
Alligator Bioscience Ab |
Method for in vitro molecular evolution of protein function
|
US20020086292A1
(en)
|
2000-12-22 |
2002-07-04 |
Shigeaki Harayama |
Synthesis of hybrid polynucleotide molecules using single-stranded polynucleotide molecules
|
GB0107661D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Staphylococcus aureus
|
GB0107658D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Streptococcus pneumoniae
|
WO2002081641A2
(en)
|
2001-04-06 |
2002-10-17 |
Georgetown University |
Gene scc-112 and diagnostic and therapeutic uses thereof
|
WO2002081639A2
(en)
|
2001-04-06 |
2002-10-17 |
Georgetown University |
Gene brcc2 and diagnostic and therapeutic uses thereof
|
WO2002081642A2
(en)
|
2001-04-06 |
2002-10-17 |
Georgetown University |
Gene brcc-3 and diagnostic and therapeutic uses thereof
|
JP4541645B2
(ja)
|
2001-04-12 |
2010-09-08 |
インペリアル・イノベイションズ・リミテッド |
I型癌の診断および治療
|
AU2002305331A1
(en)
*
|
2001-05-02 |
2002-11-11 |
Southern Research Institute |
Gene delivery compounds
|
WO2002090600A2
(en)
|
2001-05-08 |
2002-11-14 |
Darwin Molecular Corporation |
A method for regulating immune function in primates using the foxp3 protein
|
CA2452119C
(en)
|
2001-07-05 |
2013-10-15 |
Chiron Corporation |
Polynucleotides encoding antigenic hiv type b and/or type c polypeptides, polypeptides and uses thereof
|
EP1411770A4
(en)
|
2001-07-05 |
2006-05-10 |
Chiron Corp |
POLYNUCLEOTIDES CODING FOR ANTIGENIC C-TYPE HIV POLYPEPTIDES, POLYPEPTIDES AND THEIR USE
|
EP1273309A1
(de)
*
|
2001-07-05 |
2003-01-08 |
Georg-August Universität Göttingen |
Gentherapeutisches Verfahren zur Behandlung von GnRH-Rezeptor-positiven Karzinomen durch GnRH induzierte tumorzellspezifische Aktivierung eines therapeutischen Gens, zugehörige Nukleinsäurekonstrukte und Vektoren
|
WO2003004063A1
(de)
*
|
2001-07-05 |
2003-01-16 |
Georg-August Universität Göttingen |
Gentherapeutisches verfahren zur behandlung von gnrh-rezeptor-positiven karzinomen durch gnrh induzierte tumorzellspezifische aktivierung eines therapeutischen gens, zugehörige nukleinsäurekonstrukte und vektoren
|
US7037718B2
(en)
|
2001-10-26 |
2006-05-02 |
Cornell Research Foundation, Inc. |
Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof
|
US7488598B2
(en)
|
2001-10-26 |
2009-02-10 |
Cornell Center For Technology Enterprise And Commercialization |
Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof
|
MXPA04003852A
(es)
|
2001-10-26 |
2005-02-17 |
Univ Tennessee Res Foundation |
Composiciones de vacuna estreptococica multivalente, y metodos para sus uso.
|
CA2469491A1
(en)
|
2001-12-12 |
2003-06-19 |
Kerrie Setiawan |
Composition for viral preservation
|
ATE406912T1
(de)
|
2001-12-12 |
2008-09-15 |
Novartis Vaccines & Diagnostic |
Immunisierung gegen chlamydia tracheomatis
|
CA2479118A1
(en)
|
2002-03-15 |
2003-09-25 |
Wyeth Holdings Corporation |
Mutants of the p4 protein of nontypable haemophilus influenzae with reduced enzymatic activity
|
US7244565B2
(en)
|
2002-04-10 |
2007-07-17 |
Georgetown University |
Gene shinc-3 and diagnostic and therapeutic uses thereof
|
US7138512B2
(en)
|
2002-04-10 |
2006-11-21 |
Georgetown University |
Gene SHINC-2 and diagnostic and therapeutic uses thereof
|
ES2385032T3
(es)
|
2002-04-22 |
2012-07-17 |
Recopharma Ab |
Vacunas de polipéptido de fusión de mucina, composiciones y métodos de uso de las mismas
|
AU2003228751A1
(en)
|
2002-05-01 |
2003-11-17 |
Cell Genesys, Inc. |
Lentiviral vector particles resistant to complement inactivation
|
GB0308198D0
(en)
|
2003-04-09 |
2003-05-14 |
Chiron Srl |
ADP-ribosylating bacterial toxin
|
US9532994B2
(en)
|
2003-08-29 |
2017-01-03 |
The Regents Of The University Of California |
Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins
|
US8268324B2
(en)
|
2004-03-29 |
2012-09-18 |
Galpharma Co., Ltd. |
Modified galectin 9 proteins and use thereof
|
WO2007031098A1
(en)
|
2005-09-12 |
2007-03-22 |
Xigen S.A. |
Cell-permeable peptide inhibitors of the jnk signal transduction pathway
|
EP1993558B1
(en)
|
2006-02-27 |
2014-07-30 |
The Regents of The University of California |
Oxysterol compounds and the hedgehog pathway
|
GB0607354D0
(en)
|
2006-04-12 |
2006-05-24 |
Bioinvent Int Ab |
Agent, Composition And Method
|
DK2054431T3
(da)
|
2006-06-09 |
2012-01-02 |
Novartis Ag |
Konformere af bakterielle adhæsiner
|
EP2139447A2
(en)
|
2007-03-20 |
2010-01-06 |
Harold Brem |
Gm-csf cosmeceutical compositions and methods of use thereof
|
CA2707663C
(en)
|
2007-12-03 |
2017-05-30 |
The Regents Of The University Of California |
Oxysterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and wnt signaling
|
WO2009143865A1
(en)
|
2008-05-30 |
2009-12-03 |
Xigen S.A. |
Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
|
WO2009143864A1
(en)
|
2008-05-30 |
2009-12-03 |
Xigen S.A. |
Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
|
GB2460717A
(en)
|
2008-06-11 |
2009-12-16 |
Sense Proteomic Ltd |
Autoantibodies for the detection of a predisposition to Lupus
|
CN102224254A
(zh)
|
2008-09-23 |
2011-10-19 |
哈佛大学校长及研究员协会 |
Sirt4及其用途
|
US9181315B2
(en)
|
2009-01-08 |
2015-11-10 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for induced brown fat differentiation
|
WO2011038063A1
(en)
|
2009-09-28 |
2011-03-31 |
The Trustees Of The University Of Pennsylvania |
Method of diagnosing and treating interstitial cystitis
|
US20130040853A1
(en)
|
2010-01-21 |
2013-02-14 |
Dana-Farber Cancer Institute Inc. |
Context Specific Genetic Screen Platform to Aid in Gene Discovery and Target Validation
|
US9149025B2
(en)
|
2010-02-19 |
2015-10-06 |
Universite De Liege |
Polynucleotide for use in treatment of influenza A virus induced diseases, encoding modified Mx protein, said modified Mx protein, and a transgenic animal expressing gene encoding modified Mx protein
|
PL2902035T3
(pl)
|
2010-10-14 |
2019-04-30 |
Xigen Inflammation Ltd |
Przechodzące przez komórkę peptydowe inhibitory szlaku przekazywania sygnałów przez JNK do zastosowania w leczeniu chorób zapalnych oka
|
WO2012048721A1
(en)
|
2010-10-14 |
2012-04-19 |
Xigen S.A. |
Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
|
US9539427B2
(en)
|
2010-11-08 |
2017-01-10 |
The Johns Hopkins University |
Methods for improving heart function
|
US9198975B2
(en)
|
2010-12-01 |
2015-12-01 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for targeting sites of neovascular growth
|
GB201115280D0
(en)
|
2011-09-05 |
2011-10-19 |
Alligator Bioscience Ab |
Antibodies, uses and methods
|
US8969519B2
(en)
|
2011-09-13 |
2015-03-03 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for brown fat induction and activity using FNDC5
|
US10378060B2
(en)
|
2011-10-14 |
2019-08-13 |
Dana-Farber Cancer Institute, Inc. |
ZNF365/ZFP365 biomarker predictive of anti-cancer response
|
AU2012344299A1
(en)
|
2011-11-30 |
2014-05-29 |
Xigen Inflammation Ltd. |
Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of dry eye syndrome
|
KR20200075023A
(ko)
|
2012-05-04 |
2020-06-25 |
화이자 인코포레이티드 |
전립선 관련된 항원 및 백신 기재 면역치료 요법
|
JP6262723B2
(ja)
|
2012-05-07 |
2018-01-17 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California |
オキシステロールアナログoxy133は、骨発生及びヘッジホッグシグナル伝達を誘導し、脂肪生成を阻害する
|
CA2911205A1
(en)
|
2013-05-02 |
2014-11-06 |
The Regents Of The University Of California |
Bone-selective osteogenic oxysterol-bone targeting agents
|
WO2015197098A1
(en)
|
2014-06-26 |
2015-12-30 |
Xigen Inflammation Ltd. |
New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
|
WO2014206427A1
(en)
|
2013-06-26 |
2014-12-31 |
Xigen Inflammation Ltd. |
New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
|
US11624093B2
(en)
|
2014-04-24 |
2023-04-11 |
Dana-Farber Cancer Institute, Inc. |
Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
|
CA2963091A1
(en)
|
2014-10-06 |
2016-04-14 |
Dana-Farber Cancer Institute, Inc. |
Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
|
EP3204031A2
(en)
|
2014-10-08 |
2017-08-16 |
Xigen Inflammation Ltd. |
New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
|
CA2963602A1
(en)
|
2014-10-09 |
2016-04-14 |
Dana-Farber Cancer Institute, Inc. |
Multiple-variable il-2 dose regimen for treating immune disorders
|
AU2016229238B2
(en)
|
2015-03-06 |
2022-06-02 |
Dana-Farber Cancer Institute, Inc. |
PD-L2 biomarkers predictive of PD-1 pathway inhibitor responses in esophagogastric cancers
|
WO2017066561A2
(en)
|
2015-10-16 |
2017-04-20 |
President And Fellows Of Harvard College |
Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
|
WO2017075329A2
(en)
|
2015-10-29 |
2017-05-04 |
Dana-Farber Cancer Institute, Inc. |
Methods for identification, assessment, prevention, and treatment of metabolic disorders using pm20d1 and n-lipidated amino acids
|
KR20190080825A
(ko)
|
2016-03-21 |
2019-07-08 |
다나-파버 캔서 인스티튜트 인크. |
T-세포 기능소실 상태-특이적 유전자 발현 조절인자 및 그 용도
|
US20180030478A1
(en)
|
2016-07-01 |
2018-02-01 |
Research Development Foundation |
Elimination of proliferating cells from stem cell-derived grafts
|
WO2018057618A1
(en)
|
2016-09-20 |
2018-03-29 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for identification, assessment, prevention, and treatment of aml using usp10 biomarkers and modulators
|
EP3634496A4
(en)
|
2017-06-06 |
2021-09-08 |
Dana-Farber Cancer Institute, Inc. |
METHOD FOR RISING AWARENESS IN CANCER CELLS AGAINST T-CELL-MEDIATED KILLING BY MODULATING MOLECULAR SIGNAL PATHS
|
US20220289854A1
(en)
|
2019-04-30 |
2022-09-15 |
Dana-Farber Cancer Institute, Inc. |
Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents
|
EP4343004A2
(en)
|
2020-10-19 |
2024-03-27 |
Dana-Farber Cancer Institute, Inc. |
Germline biomarkers of clinical response and benefit to immune checkpoint inhibitor therapy
|
US20240024474A1
(en)
|
2020-11-13 |
2024-01-25 |
David Avigan |
Personalized fusion cell vaccines
|
WO2022159793A2
(en)
|
2021-01-25 |
2022-07-28 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for identifying neuroendocrine prostate cancer
|
WO2022261183A2
(en)
|
2021-06-08 |
2022-12-15 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
|
WO2023097119A2
(en)
|
2021-11-29 |
2023-06-01 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions to modulate riok2
|
WO2023158732A1
(en)
|
2022-02-16 |
2023-08-24 |
Dana-Farber Cancer Institute, Inc. |
Methods for decreasing pathologic alpha-synuclein using agents that modulate fndc5 or biologically active fragments thereof
|
LT7046B
(lt)
|
2022-04-15 |
2024-02-12 |
Vilniaus Universitetas |
Hidrolazės ir jų panaudojimas
|